Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Beta Bionics, Inc.NASDAQ: BBNX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $25.21M (cash outflow) rose 24.1% year over year, ahead of the +2.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 139.4% from the prior quarter. Over 3 fiscal years it compounded at -2.7% a year.
Context
- Free cash flow amounted to 56.1% of revenue in FY2025, down 23.3 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +24.1% holds above the trailing-twelve-month pace of +2.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (56.22M) USD
- Year-over-year change
- -8.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (56.22M) | -8.8% |
| FY2024 | 2024-12-31 | (51.67M) | -57.3% |
| FY2023 | 2023-12-31 | (32.85M) | +46.1% |
| FY2022 | 2022-12-31 | (60.98M) | — |
Free Cash Flow vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.9% is the 2nd highest of 7, against a peer median of -18.6%.
- Free cash flow amounts to 55.4% of revenue for BBNX, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 48.92B DKK | -20.6% | -23.3% | 14.8% | |
| LTM Jun 2026 | $1.41B USD | +146.1% | +52.3% | 28.3% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $316M USD | — | +34.4% | 9.8% |
| LTM Jun 2026 | $298.3M USD | -23.2% | — | 9.8% | |
| LTM Mar 2026 | $61.12M USD | +2.9% | -2.7% | 55.4% | |
| LTM Mar 2026 | $12.72M USD | -41.7% | — | 3.5% | |
| LTM Mar 2026 | $8.74M USD | -16.5% | -27.6% | — | |
| LTM Mar 2026 | $3.64M USD | -4.1% | — | 0.4% | |
| Peer median (excluding BBNX) | — | -18.6% | +5.6% | 9.8% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Depreciation & Amortization | 2.09M | 2.09M | 2.28M | 2.88M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 5.66M | 6.38M | 16.38M |
| Change in Working Capital | (2.79M) | (6.36M) | (12.15M) | (8.99M) |
| Accounts Receivables | 0 | (4.49M) | (7.62M) | (5.16M) |
| Inventory | 0 | (1.19M) | (11.44M) | (9.88M) |
| Accounts Payables | (77K) | 716K | 1.52M | 2.1M |
| Other Working Capital | (2.71M) | (682K) | 5.39M | 3.95M |
| Other Non-Cash Items | (854K) | 10.27M | 9.96M | 12.01M |
| Operating Cash Flow | (60.21M) | (32.45M) | (48.27M) | (50.93M) |
| Capital Expenditures | (772K) | (402K) | (3.4M) | (5.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (69.3M) | (72.13M) | (327.51M) |
| Sales of Investments | 0 | 0 | 72M | 170M |
| Other Investing Activities | 3K | (69.29M) | 50K | 0 |
| Investing Cash Flow | (769K) | (69.69M) | (3.48M) | (162.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 389K | 29K | 55.62M | 214.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 389K | 101.03M | 0 | 0 |
| Financing Cash Flow | 56.78M | 101.03M | 55.62M | 214.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.2M) | (1.11M) | 3.87M | 1.14M |
| Free Cash Flow | (60.98M) | (32.85M) | (51.67M) | (56.22M) |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.